Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 22 at 2:00 PM EDT

Register Free →

Multiscale Reasoning For Human Physiology RFI

Active
DARPA-SN-26-100Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Defense Advanced Research Projects Agency’s Biological Technologies Office is seeking input on cutting-edge technologies that enable multiscale reasoning across human physiology through this Request for Information, identified as DARPA-SN-26-100. The focus is on emerging tools including artificial intelligence systems, foundation models, computational frameworks, and datasets capable of integrating biological, physiological, and clinical data across multiple scales—from molecular and cellular levels to organ systems and whole-body responses. The goal is to advance the ability to model, predict, and interpret complex human physiological behavior using AI and data-driven approaches, with interest in non-traditional performers and innovative solutions from industry, academia, government labs, and healthcare organizations. Responses are due by August 10, 2026, and the solicitation falls under NAICS code 541714 for research and development in the physical, engineering, and life sciences. All submissions should be directed to Dr. Roozbeh Jafari, Program Manager at DARPA/BTO, via bioreasoning@darpa.mil. The office is located in Arlington, Virginia, and while no specific place of performance is defined, selected technologies may be developed and evaluated through future DARPA programs. This RFI does not constitute a solicitation for proposals or obligations but aims to inform upcoming funding opportunities in the field of physiological modeling and AI-driven biological insight.

General Info

DARPA seeks AI-driven multiscale physiological modeling tech via RFI due August 10, 2026, from diverse innovators.

Agency

Department Of Defense → Defense Advanced Research Projects AgcyView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

VA

Set-Aside

NONE

Documents

(1)

DARPA-SN-26-100.pdf

PDF

AI Contract Breakdown

Uniform Contract Format

What is UCF?

Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.

Timeline

Posted

special-notice

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Advanced Research Projects Agcy
Contacts1 person available
OfficeARLINGTON, VA, 222032114, USA
Organization / Agency
Department Of Defense → Defense Advanced Research Projects Agcy
View Agency Profile
Office AddressARLINGTON, VA, 222032114, USA
Contacts
Dr. Roozbeh Jafari Program Manager DARPA/BTO

Full Description

Show more
The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) is issuing this Request for Information (RFI) to solicit input from industry, academia, government laboratories, healthcare organizations, and non-traditional performers regarding emerging technologies, datasets, computational frameworks, artificial intelligence systems, and foundation models that enable multiscale reasoning across human physiology.

Similar Contracts

NAICS: 541714
New
Grant
Advancing Outbreak Detection, Notification, and Response Capacity by Implementing 7-1-7 in Partner CountriesThis funding opportunity supports the strengthening of national systems in partner countries to achieve the 7-1-7 target for outbreak detection, notification, and response, with the goal of containing biological threats before they spread across borders. Activities are focused on enhancing early warning surveillance, expanding laboratory capacity, improving information sharing across sectors and international boundaries, and building robust response operations to minimize health and economic impacts. The initiative leverages lessons from past global health emergencies to protect both U.S. interests and the health security of recipient nations by promoting efficient, accountable, and sustainable systems that reduce reliance on external support over time. Funded through the Centers for Disease Control and Prevention under the U.S. Department of Health and Human Services, this solicitation is open to applicants seeking to implement activities exclusively outside the United States and its territories. Applications must be submitted by August 14, 2026, under solicitation number CDC-RFA-JG-26-0214, with inquiries directed to the designated point of contact at the CDC. The program emphasizes burden sharing and long-term self-reliance, aiming to foster resilient health systems that not only safeguard local populations but also enhance global health security in alignment with American strategic interests.
Centers For Disease Control-Ghc

POSTED

about 23 hours ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Grant
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)The National Cancer Institute is soliciting R33 grant applications to support the advanced development and rigorous validation of emerging technologies aimed at advancing cancer research and clinical care. This opportunity is intended for projects that have already addressed major feasibility barriers, as demonstrated by strong preliminary data, but require further refinement, optimization, and technical validation to achieve broad adoption within the scientific community. The focus is on technologies with new or substantially improved capabilities for measuring, analyzing, modeling, or interrogating cancer-related biological systems, including advanced molecular and cellular platforms, multi-omic and spatial profiling methods, next-generation imaging and sensing tools, immuno-engineering approaches, and innovations in biospecimen handling and quality assessment. Proposals must center on cancer-specific applications, and applications that merely apply established technologies to novel biological questions without technological innovation are not eligible. This funding opportunity is part of the NCI’s Innovative Molecular Analysis Technologies Program and explicitly prohibits clinical trials. The goal is to accelerate progress in areas such as cancer biology, early detection, diagnosis, treatment, control, and epidemiology by enabling technologies that offer transformative potential for the research community. Projects must demonstrate clear potential for widespread utility in cancer research while maintaining a tight focus on technical advancement rather than application-specific hypotheses. All applications must be submitted through the designated grants portal, and inquiries should be directed to the IMAT Program Contact provided. The opportunity was posted in July 2026 and is open to applicants seeking to bridge the gap between initial innovation and scalable adoption in cancer science.
National Institutes Of Health

POSTED

about 23 hours ago

DEADLINE

N/A
View Details